Legal status · United States
Is Relaxin-2 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Relaxin-2 is not an approved medicine in the United States; its classification is "Not a medicine; endogenous signalling molecule". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Relaxin-2 in the United States at a glance
| Classification | Not a medicine; endogenous signalling molecule |
|---|---|
| Note | Relaxin-2 is a hormone produced by the corpus luteum and placenta. Its recombinant form, serelaxin, is not FDA-approved: RELAX-AHF-2 missed both primary endpoints in 6,545 patients and development for acute heart failure stopped. No approved medicine acts at RXFP1. Long-acting relaxin fusions such as AZD3427 remain investigational. |
| FDA approval status | Relaxin-2 is an endogenous hormone. Serelaxin, its recombinant form, is not approved by the FDA or any other regulator. It received attention after the RELAX-AHF result but the confirmatory RELAX-AHF-2 trial failed both primary endpoints and development for acute heart failure was discontinued. |
| Human studies cited | 3 of 5 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Relaxin-2 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Relaxin-2 is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Relaxin-2 is
The pregnancy hormone that opens the circulation. A 1,161 patient phase 3 trial reported 42 deaths against 65 on placebo at 180 days as an additional endpoint, and the 6,545 patient confirmatory trial found cardiovascular death of 8.7 percent against 8.9 percent, hazard ratio 0.98. Serelaxin was never approved and development for acute heart failure stopped.
Relaxin-2 is a two-chain peptide hormone of the insulin superfamily, made by the corpus luteum and the placenta, and it is the reason a pregnant woman's cardiac output rises and her blood vessels and kidneys relax. That physiology is not in question and it is a perfectly good reason to have wondered whether the same hormone could help a failing heart.
Mechanism: Relaxin-2 acts at RXFP1, a G protein-coupled receptor, and produces systemic vasodilation, increased cardiac output, increased renal blood flow and increased arterial compliance, largely through nitric oxide and cyclic AMP dependent pathways, together with anti-fibrotic signalling that has been the focus of most later work. It is a two-chain molecule held together by disulfide bonds, built like insulin, which is why it is hard and expensive to manufacture and why simplified single-chain analogues were designed.
Regulatory history: Relaxin-2 is an endogenous hormone. Serelaxin, its recombinant form, is not approved by the FDA or any other regulator. It received attention after the RELAX-AHF result but the confirmatory RELAX-AHF-2 trial failed both primary endpoints and development for acute heart failure was discontinued.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Relaxin-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Relaxin-2 in other countries
United Kingdom
Not approvedNot a medicine; endogenous signalling molecule
Is Relaxin-2 legal in the United Kingdom?Australia
Not approvedNot a medicine; endogenous signalling molecule
Is Relaxin-2 legal in Australia?Canada
Not approvedNot a medicine; endogenous signalling molecule
Is Relaxin-2 legal in Canada?Frequently asked questions
Is Relaxin-2 legal in the United States?
No. Relaxin-2 is not an approved medicine in the United States; its classification is "Not a medicine; endogenous signalling molecule". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: Relaxin-2 is a hormone produced by the corpus luteum and placenta. Its recombinant form, serelaxin, is not FDA-approved: RELAX-AHF-2 missed both primary endpoints in 6,545 patients and development for acute heart failure stopped. No approved medicine acts at RXFP1. Long-acting relaxin fusions such as AZD3427 remain investigational.
Can I buy Relaxin-2 in the United States?
No approved product exists to buy. In the United States Relaxin-2 is classified as "Not a medicine; endogenous signalling molecule", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Relaxin-2 is a hormone produced by the corpus luteum and placenta. Its recombinant form, serelaxin, is not FDA-approved: RELAX-AHF-2 missed both primary endpoints in 6,545 patients and development for acute heart failure stopped. No approved medicine acts at RXFP1. Long-acting relaxin fusions such as AZD3427 remain investigational.
Is Relaxin-2 FDA approved?
No. FDA status: Relaxin-2 is an endogenous hormone. Serelaxin, its recombinant form, is not approved by the FDA or any other regulator. It received attention after the RELAX-AHF result but the confirmatory RELAX-AHF-2 trial failed both primary endpoints and development for acute heart failure was discontinued.. Current US classification: "Not a medicine; endogenous signalling molecule". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Relaxin-2 live on its compound profile.
Relaxin-2 profileThis page is general information about the regulatory status of Relaxin-2 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.